What are the latest figures on the gliosarcoma market’s size and projected CAGR?
The gliosarcoma market size has grown strongly in recent years. It will grow from $1.19 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to an increase in healthcare expenditure, a rising number of clinical trials, an increase in the global aging population, a growing prevalence of comorbidities like diabetes and hypertension, and an increase in healthcare insurance coverage.
The gliosarcoma market size is expected to see strong growth in the next few years. It will grow to $1.54 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing incidence of gliosarcoma, rising awareness about brain cancers, growth in research funding for brain cancer, rising demand for personalized treatments, and expansion of healthcare infrastructure. Major trends in the forecast period include advances in diagnostic techniques, development of targeted therapies, availability of advanced imaging technologies, advancements in surgical techniques, and technological innovations in drug delivery systems.
Get Your Free Sample of The Global Gliosarcoma Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21192&type=smp
Which Market drivers have played a significant role in driving the gliosarcoma market?
The increasing incidence of brain tumors is expected to propel the growth of the gliosarcoma market going forward. A brain tumor is an abnormal growth of cells in the brain, which can be benign or malignant and may cause symptoms like headaches, seizures, and vision problems. The incidence of brain tumors is rising due to improved diagnostic technologies, increased awareness, and potential environmental and lifestyle factors contributing to higher exposure to risk factors. Gliosarcoma treatment is essential for brain tumors because it targets this aggressive and rare cancer, aiming to manage symptoms, prolong survival, and improve the patient’s quality of life. For instance, in October 2022, according to the National Library of Medicine, a US-based biomedical library operated by the United States federal government, in 2023, the United States reported 94,390 new cases of brain and CNS tumors, reflecting a slight increase from 93,470 cases in 2022, with malignant cases rising from 26,670 to 26,940 and non-malignant cases growing from 66,800 to 67,440. Therefore, the increasing incidence of brain tumors is driving the growth of the gliosarcoma market.
What are the key segments within the gliosarcoma market?
The gliosarcoma market covered in this report is segmented –
1) By Diagnosis Method: Imaging Techniques, Histopathological Examination, Biomarker Testing
2) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy
3) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics
Subsegments:
1) By Imaging Techniques: Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan, Positron Emission Tomography (PET) Scan
2) By Histopathological Examination: Hematoxylin and Eosin (H&E) Staining, Immunohistochemistry (IHC), Electron Microscopy
3) By Biomarker Testing: IDH Mutation Testing, MGMT Promoter Methylation Testing, ATRX Mutation Testing, TP53 Mutation Analysis
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/gliosarcoma-global-market-report
Which key players are shaping the gliosarcoma market?
Major companies operating in the gliosarcoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma, Bio-Rad Laboratories Inc., Carl Zeiss AG, Elekta AB, Novocure Ltd., ImmunityBio Inc., Immatics Biotechnologies, Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., Komipharm International Co. Ltd., Kintara Therapeutics Inc., Aveta Biomics Inc., Vigeo Therapeutics Inc.
Which transformative trends will shape the gliosarcoma market landscape?
Major companies operating in the gliosarcoma market are focusing on developing technologically advanced products, such as wearable devices, to provide convenient, continuous monitoring of health and activity data, offering real-time insights and enhancing user engagement with their wellness goals. Wearable devices are electronic gadgets designed to be worn on the body that monitor, track, or enhance various aspects of health, fitness, or daily activities. For instance, in November 2024, Novocure Ltd., a UK-based oncology company, announced the U.S. Food and Drug Administration (FDA) approval for the use of Head Flexible Electrode (HFE) transducer arrays alongside Optune Gio for treating adult patients with glioblastoma multiforme (GBM). The Optune Gio is a portable, wearable device that uses non-invasive wearable arrays to provide tumor-treating fields (TTFields), which apply physical forces to the electrically charged parts of dividing cancer cells to stop their fast division. The new HFE arrays are 50% thinner and one-third lighter than the ceramic discs found in the existing Optune Gio arrays because they are composed of a flexible polymer substance. This improves patient comfort and use.
How do regional factors impact the gliosarcoma market, and which region is the largest contributor?
North America was the largest region in the gliosarcoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gliosarcoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Gliosarcoma Market Report 2025 Offer?
The gliosarcoma market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Gliosarcoma refers to a rare and aggressive brain tumor that consists of both glial and sarcomatous tissue, typically occurring in the cerebral hemisphere. They are used for studying tumor biology and developing treatment strategies for glioblastoma and other brain malignancies.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21192
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
